logo

Casi Pharmaceuticals, Inc. (CASI)



Trade CASI now with
  Date
  Headline
9/19/2019 7:17:58 AM CASI Pharmaceuticals Promotes Larry Zhang To President
9/16/2019 6:03:23 AM China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product
8/12/2019 7:02:12 AM CASI Pharma Announces Launch Of EVOMELA In China
8/9/2019 7:10:58 AM CASI Pharma Q2 Net Loss $15.3 Mln Or $0.16/Shr Vs Loss $5.9 Mln Or $0.07/Shr Last Year
5/15/2019 7:49:48 AM CASI Pharma Q1 Net Loss $8.2 Mln Or $0.09/Shr Vs Loss $3.6 Mln Or $0.05/Shr Last Year
4/2/2019 7:05:25 AM CASI Pharma Announces Appointment Of Wei-Wu He, Executive Chairman, To The Role Of CEO
3/29/2019 7:08:16 AM CASI Pharma FY Net Loss $27.5 Mln Or $0.32/Shr Vs Loss Of $10.8 Mln Or $0.18/Shr Last Year
3/13/2019 7:03:52 AM China Resources Guokang Pharma To Be Sole Distributor For Sale Of Melphalan Hydrochloride For Injection In China
3/7/2019 7:11:03 AM CASI Announces China Approval Of CTA To Conduct Registration Trial For MARQIBO
12/3/2018 8:13:22 AM CASI Pharma Reports China Market Approval Of Melphalan Hydrochloride For Injection
11/16/2018 7:06:18 AM CASI Pharma To Build GMP Manufacturing Site In Wuxi, China
11/14/2018 7:08:40 AM CASI Pharma Q3 Loss Attributable To Common Shareholders $8.8 Mln Or $0.10/Shr Vs Loss $1.6 Mln Or $0.03/Shr Last Year
10/23/2018 7:07:56 AM CASI Pharmaceuticals Acquires A U.S. FDA-approved ANDA From Laurus Labs
9/28/2018 7:05:10 AM CASI Pharma Appoints George Chi As CFO
9/14/2018 7:02:13 AM CASI Pharmaceuticals Announces $48.5 Mln Private Placement
8/14/2018 7:04:47 AM CASI Pharma Q2 Net Loss Attributable To Shareholders $5.9 Mln Or $0.07/Shr Vs Loss $2.4 Mln Or $0.04/Shr Last Year
5/15/2018 7:09:55 AM CASI Pharma Q1 Net Loss $3.6 Mln Or $0.05/Shr Vs Loss $1.7 Mln Or $0.03/Shr Last Year
  
 
>